Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
02 févr. 2023 08h00 HE
|
Protara Therapeutics
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
30 janv. 2023 08h00 HE
|
Protara Therapeutics
NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
01 déc. 2022 08h00 HE
|
Protara Therapeutics
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview
03 nov. 2022 08h00 HE
|
Protara Therapeutics
- Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Administration,...
Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 08h00 HE
|
Protara Therapeutics
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview
09 août 2022 08h00 HE
|
Protara Therapeutics
- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash Equivalents and Investments Position of $112.8M as of...
Protara Therapeutics Announces Departure of Chief Financial Officer
21 juin 2022 08h00 HE
|
Protara Therapeutics
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
26 mai 2022 17h11 HE
|
Protara Therapeutics
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference
17 mai 2022 08h00 HE
|
Protara Therapeutics
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
12 mai 2022 08h00 HE
|
Protara Therapeutics
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...